AstraZeneca’s COVID-19 vaccine 70% effective
AstraZeneca’s COVID-19 vaccine 70% effective. AstraZeneca’s COVID-19 vaccine has an average effectiveness of 70%, which is lower than Pfizer and Moderna. On November 23, AstraZeneca announced that its COVID-19 vaccine AZD1222 in cooperation with Oxford University is effective against the COVID-19 virus, with an average effectiveness of 70%.
The effectiveness of Pfizer’s COVID-19 vaccine is 95%, and the effectiveness of Moderna is 94.5%. AstraZeneca’s COVID-19 vaccine is less effective than the former two.
It is worth noting that the results of the two different dosage methods announced by AstraZeneca are very different. When AZD1222 is vaccinated with a half dose, at least one month apart and then vaccinated with a full dose, the effectiveness of the vaccine is 90%.
Another vaccination scheme showed that the effectiveness of two full-dose vaccination at least one month apart was only 62%. At present, the company has not disclosed the reason for the better effect of the first half-dose injection, and the better results of lower-dose effectiveness deviate from our understanding.
Data source: Announcement, compiled by Futu Securities Data source: Announcement, compiled by Futu Securities
In addition, on September 8th, AstraZeneca decided to suspend its clinical trials of the COVID-19 vaccine in many places around the world due to a “possibly unexplainable disease” in a subject.
Later, the company continued to restart AZD1222 clinical trials in various countries. According to the current disclosed data, AstraZeneca announced that the adenovirus vaccine AZD1222 has reached the primary endpoint of preventing COVID-19 pneumonia.
AstraZeneca’s COVID-19 vaccine is expected to be approved in early 2021
Currently, eleven new coronavirus vaccines have entered phase III clinical trials in the world, five vaccines have entered phase III clinical trials in China, and about four in the United States. AstraZeneca suspended its global clinical trial of the COVID-19 vaccine in September, so the progress of the clinical trial has been delayed. It is expected to be approved for marketing in early 2021.
AstraZeneca has the world’s largest COVID-19 vaccine production capacity
AstraZeneca has the world’s largest COVID-19 vaccine production capacity, and its adenovirus vector vaccine storage conditions are 2°-8°. AstraZeneca will have an annual production capacity of 3 billion doses of COVID-19 vaccines in the future. With its strong scale effect, its price is the lowest of all COVID-19 vaccines.
The cold chain problem encountered by the mRNA COVID-19 vaccine before, AstraZeneca’s adenovirus vector vaccine storage conditions are 2°-8°. AstraZeneca said the vaccine can be stored, transported and processed under normal cold storage conditions (2-8 degrees Celsius) for at least six months, and can be used in existing medical institutions.